Immuneering (IMRX) Retained Earnings (2020 - 2024)
Immuneering has reported Retained Earnings over the past 5 years, most recently at -$206.2 million for Q3 2024.
- Quarterly results put Retained Earnings at -$206.2 million for Q3 2024, down 39.19% from a year ago — trailing twelve months through Sep 2024 was -$206.2 million (down 39.19% YoY), and the annual figure for FY2023 was -$163.3 million, down 48.7%.
- Retained Earnings for Q3 2024 was -$206.2 million at Immuneering, down from -$1084.0 in the prior quarter.
- Over the last five years, Retained Earnings for IMRX hit a ceiling of -$1084.0 in Q1 2024 and a floor of -$206.2 million in Q3 2024.
- Median Retained Earnings over the past 5 years was -$49.6 million (2021), compared with a mean of -$67.7 million.
- Biggest five-year swings in Retained Earnings: plummeted 103902.22% in 2023 and later soared 100.0% in 2024.
- Immuneering's Retained Earnings stood at -$25.7 million in 2020, then tumbled by 130.3% to -$59.3 million in 2021, then plummeted by 85.22% to -$109.8 million in 2022, then tumbled by 48.7% to -$163.3 million in 2023, then decreased by 26.33% to -$206.2 million in 2024.
- The last three reported values for Retained Earnings were -$206.2 million (Q3 2024), -$1084.0 (Q1 2024), and -$163.3 million (Q4 2023) per Business Quant data.